What Corvental-D Treats: Main Uses and Benefits

Corvental-D (Choline Theophyllinate) is commonly used to provide targeted symptomatic support in canine medicine for chronic conditions that generally involve significant impact on a dog's respiratory and overall functional stability. This medication is applied across therapeutic domains where additional symptomatic support is needed.

---

The medicine is commonly used for managing symptom clusters associated with chronic lower airway disease (like chronic bronchitis) and may be part of symptomatic management for patients with congestive heart failure (CHF).

“This supportive relief contributes to easing the overall symptom load and is relevant when symptoms interfere with routine activities.”

It helps manage persistent and distressing manifestations such as harsh, recurrent coughing and pronounced wheezing, and may also assist with managing generalized lethargy and poor exercise tolerance linked to systemic strain. The main therapeutic goal is to support the opening of the airways, which contributes to improved comfort by easing the physical work required for breathing.

Quick Fact: Symptomatic Support
Corvental-D is generally used in long-term scenarios to manage symptoms arising from inflammatory or irritative states that interfere with daily functioning, assisting with maintaining functional stability in dogs with chronic respiratory issues.

Who Can and Cannot Use Corvental-D?

Corvental-D (Choline Theophyllinate) is a veterinary medicinal product whose official eligibility profile applies exclusively to the target species: dogs. Regulatory labeling strictly defines specific populations for whom the medicine is either contraindicated or requires conditional use.

The medicine must not be used in dogs with a known history of epileptiform seizures. It is also contraindicated if the dog is concurrently receiving beta-sympathomimetics. These prohibitions represent absolute non-eligibility based on safety documented in the official labeling.

Use is restricted or requires special caution in certain physiological states. The active substance should be used with caution in dogs diagnosed with liver disease (hepatic impairment). For pregnant bitches and lactating bitches, use requires a formal risk-benefit assessment before administration, as small amounts are excreted in milk. Official documentation does not list specific age-related restrictions for puppies or older dogs. The overall eligibility is defined by the absence of these specific comorbidities and drug-use conflicts.

Interactions with other medicines and products

Official regulatory documentation identifies specific medicinal products and substances that formally interact with Corvental-D (Choline Theophyllinate), resulting in significant changes to its plasma concentration or heightened risk of pharmacodynamic effects.

Contraindicated and High-Risk Combinations

Concurrent use of beta-sympathomimetics is strictly contra-indicated due to the documented risk of additive or synergistic interactions that may result in exaggerated side effects. Administration of the medicine shortly before Halothane anaesthesia may result in arrhythmogenic effects, and co-administration with Ketamine may reduce the convulsive threshold.

---

Exposure-Modifying Substances

Interactions often occur through the alteration of theophylline clearance, which is primarily a pharmacokinetic process.

Interaction Type	Interacting Agent	Official Outcome
Increase Exposure	Macrolide Antibiotics (e.g., Erythromycin), Fluoroquinolone Antibiotics (e.g., Enrofloxacin)	May increase plasma levels due to reduced clearance.
Decrease Exposure	Phenobarbitone, Phenytoin	May decrease plasma levels due to increased clearance.

---

Substance and Population Considerations

Tobacco Smoking is documented to increase the metabolic clearance of the active substance, which can lead to decreased effectiveness. High intake of Caffeine may increase central nervous system side effects due to additive xanthine-related stimulation. Caution is noted for use in patients with Liver Disease (Hepatic Impairment), as reduced clearance in this population heightens the risk of adverse outcomes from co-administered agents.

How Corvental-D Works

Corvental-D, containing Theophylline, exerts its effects primarily through two independent mechanisms targeting specific regulatory pathways within the respiratory and cardiovascular systems.

The core mechanism involves the inhibition of phosphodiesterase (PDE) enzymes, specifically PDE3 and PDE4. This enzyme-mediated action elevates intracellular levels of cyclic adenosine monophosphate (cAMP) within bronchial smooth muscle cells. The resultant increase in cAMP initiates a cascade that promotes the relaxation of airway muscles, which influences the physical dimensions of the respiratory passages.

Secondarily, Theophylline functions as a non-selective competitive antagonist of adenosine receptors (A1 and A2 subtypes). This action prevents the binding of endogenous adenosine, thereby modulating central nervous system activity and associated peripheral effects. Additionally, the mechanism influences the direct enhancement of calcium flux within the diaphragm and skeletal muscle fibers, increasing the capacity for force generation.

Corvental-D is administered exclusively via the oral route as a sustained-release hard capsule to dogs. This sustained-release format dictates the drug’s frequency and administration pattern.

---

Dosing and Frequency

The fundamental dosing principle requires that the patient is weighed carefully and accurately to ensure the correct amount is given. The schedule involves a dose of 20 mg per kg bodyweight of the active component, Theophylline, which is administered once daily. The dose administered must not exceed this 20 mg/kg bodyweight maximum.

Administration and Adjustment Logic

The administration schedule is flexible regarding mealtimes, as the capsule may be given with food. For patients requiring fine-tuned dosing, the sustained-release capsule may be split to accommodate precise, weight-based needs.

Clinical considerations establish specific conditions for dosage modification: the medicine should be used with caution in patients identified with hepatic impairment (liver disease). Furthermore, if the patient exhibits vomiting, the dosage must be either reduced or the treatment discontinued. This guidance defines the standardized, response-driven approach to using the medicine over a potentially long-term course.

Research Evidence / Overview of Studies for Corvental-D

This overview summarizes the types of research and clinical evaluations conducted for Choline Theophyllinate (Corvental-D), focusing on what is known—and what is still uncertain—about the evidence base according to scientific and regulatory sources.

---

Evidence for Chronic Lower Airway Disease

Research on Choline Theophyllinate was studied for conditions marked by functional limitations, such as chronic bronchitis. The evidence includes Pharmacokinetic (PK) studies in the target species and Randomized Controlled Trials (RCTs) of the parent compound (Theophylline) in human respiratory conditions. PK findings describe patterns observed in the studies regarding the plasma drug concentration, aiming to describe the concentration levels evaluated. Uncertainty exists due to extrapolation from human trials and high individual variability in metabolism, with limited dedicated, long-term RCTs for this specific veterinary formulation.

---

Evidence for Supportive Treatment in Congestive Heart Failure

The evidence for using Choline Theophyllinate as a supportive treatment in patients with congestive heart failure (CHF) is derived from regulatory documentation and clinical experience. Research examined the properties of the Xanthine drug class for outcomes related to systemic or functional imbalance. Studies monitored the drug’s use as an adjunct (additional treatment) associated with outcomes related to physical discomfort, often alongside primary cardiac medications. Certainty remains low for its isolated supportive role due to the paucity of dedicated trials and the complexity of multi-drug protocols.

---

Long-Term Research and Evidence Gaps

Research exploring short-term symptom changes was conducted over defined time intervals (days to weeks). While the medication was observed in long-term clinical use, there is limited information for long-term outcomes or durability of effect. Data for certain groups remain insufficient, particularly those with significant comorbidities. Evidence quality varies across studies, and comparative evidence is lacking in the veterinary literature. Finally, the fact that long-term effects are not fully established and metabolism is highly variable means the available research provides context but not individual predictions.

Key Studies & References

1. Veterinary Medicines Directorate (VMD) Product Information Database: Corvental-D 200 mg Capsules (Choline Theophyllinate)
2. Pharmacokinetics of a sustained-release choline salt of theophylline (Oxtriphylline) in dogs.

Common questions about Corvental-D (FAQ)

---

Q: What are the two primary health conditions Corvental-D is used to treat in dogs?

Official product information states that Corvental-D is indicated for the treatment of two primary chronic conditions in dogs. These conditions are bronchitis (a lower airway disease) and congestive heart failure. Its use is indicated for both respiratory and cardiovascular conditions.

---

Q: How does Corvental-D work to help a dog with congestive heart failure?

Regulatory documents describe the medicine's supportive mechanism in heart conditions. The active substance, Theophylline, is described as dilating coronary arteries and may influence the strength of contraction of the myocardium, which is the heart muscle itself.

---

Q: Is theophylline, the drug in Corvental-D, related to common substances like caffeine?

Yes, Theophylline, the active substance in Corvental-D, is chemically similar to caffeine. Both belong to the same pharmacological group called dimethylated xanthines, which also includes theobromine.

---

Q: Is Corvental-D an extended-release medicine, and how does this affect giving it?

Corvental-D is a sustained-release formulation. This design is associated with longer intervals between doses compared to immediate-release products. Official information indicates that administering the medicine with food may slow the absorption rate, but does not reduce the overall amount absorbed.

---

Q: How long does the effect of one dose of Corvental-D typically last?

The formulation of Corvental-D is designed for once-daily administration, which is consistent with its intent to maintain therapeutic levels over a sustained period. While the half-life of Theophylline in humans is known to be several hours, official information regarding the exact duration in dogs is more limited.

---

Q: Can giving Corvental-D with certain other heart or lung medications lead to increased side effects?

Regulatory documents caution that Corvental-D can interact with other medicines. Specifically, the concurrent use of beta-sympathomimetics (a class of heart and lung drugs) is contra-indicated. This classification indicates a potential risk of exaggerated or additive side effects.

---

Q: What information is available about the difference between Corvental-D and other theophylline brands?

Corvental-D is a specific sustained-release capsule presentation known as the "Divido" formulation. This specific design controls the rate of drug release to promote steady concentration levels. This sustained-release feature differentiates it from immediate-release versions of theophylline.

---

Q: Is Corvental-D a treatment intended for short-term or long-term management of chronic conditions?

Official indications confirm the medicine is intended for the management of chronic health issues. This includes long-term conditions like chronic bronchitis and congestive heart failure. The medicine’s indication for chronic conditions suggests its use often involves long-term supportive care.

---

Q: Are there different capsule strengths of Corvental-D available?

According to the official product information, Corvental-D Hard Capsules are available in three different strengths of the active substance, Theophylline: 100 mg, 200 mg, and 500 mg.

---

Q: Is it necessary to weigh the dog accurately every time before administering Corvental-D?

Official instructions require that dogs are weighed carefully and accurately when the dose is being determined. Careful weighing is required to ensure that the maximum prescribed dose based on the patient's bodyweight is not exceeded.

---

Q: Is Corvental-D only available for purchase with a valid veterinary prescription?

Yes, Corvental-D is classified as a Prescription Only Medicine – Veterinarian (POM-V). This classification means the product can only be legally supplied based on a valid prescription issued by a licensed veterinarian.

---

Q: What are the inactive ingredients or colorants used in Corvental-D capsules?

The capsules contain the active ingredient along with various inactive ingredients, known as excipients. These include colorants detailed in official composition documents, such as Quinoline yellow (E104), Indigotine (E132), and Titanium dioxide (E171).

---

Q: Does Corvental-D reduce fluid buildup in the lungs associated with heart failure?

Regulatory documents indicate that the active substance, Theophylline, acts on the kidney to induce a process called diuresis. Diuresis is an increase in urination, which is a function that may contribute to the management of fluid accumulation often associated with heart failure.

---

Q: What are the general warnings on the package regarding accidental human ingestion of Corvental-D?

The official package warnings state that if the product is accidentally ingested by a person, regulatory warnings advise seeking medical advice immediately. Regulatory documents recommend showing the physician the package leaflet or label for proper information and safety assessment.

How to Store and Dispose of Corvental-D

Corvental-D capsules must be stored according to official labeling to maintain product stability and safety. The medicine must not be stored above 30 C and should be kept in a dry place. To protect the product, the blisters must remain in the outer carton.

Storage Requirements

Condition	Requirement
Temperature	Store not above 30 C
Protection	Store in a dry place
Safety	Keep out of the reach and sight of children
Shelf Life	5 years as packaged for sale

All unused veterinary medicinal product or waste materials derived from Corvental-D must be disposed of in accordance with local regulatory requirements.